Provided by: Chunghwa Chemical Synthesis & Biotech Co.,Ltd
SEQ_NO
7
Date of announcement
2022/05/25
Time of announcement
17:21:07
Subject
Announcement of Key Resolutions of CCSB 2022
Annual General Shareholders' Meeting.
Date of events
2022/05/25
To which item it meets
paragraph 18
Statement
1.Date of the shareholders meeting:2022/05/25
2.Important resolutions (1)Profit distribution/ deficit
compensation:
Ratification of the distribution of 2021 earnings. Cash dividend to
shareholders totals NT$100,828,000. (The cash dividend is NT$1.3 per share)
3.Important resolutions (2)Amendments to the corporate charter:
Approval to amend partial Articles of the Company's Corporate Charter.
4.Important resolutions (3)Business report and financial statements:
Ratification of the business report and financial statements of 2021.
5.Important resolutions (4)Elections for board of directors and
supervisors:
To elect Directors (including independent directors)
Newly elected Directors：
Representative of CHINA CHEMICAL & PHARMACEUTICAL CO., LTD./
WANG HSIEH YI-CHEN
Representative of CHINA CHEMICAL & PHARMACEUTICAL CO., LTD./
WANG, HOU-KAI
Representative of WANG MING-NING MEMORIAL FOUNDATION./
HUANG ,JONG-SHINN
Representative of WANG MING-NING MEMORIAL FOUNDATION./
WANG, HOU -JIE
Newly elected Independent Directors：
WANG ,KUO-CHIANG
CHANG ,CHIH-HSIEN
KUAN ARTHUR
6.Important resolutions (5)Any other proposals:
a.Approval to amend partial Articles of the Regulations Governing
the Acquisition or Disposal of Assets.
b.Approval to Intend Private Placement for Issuance of Common
Stock Shares or Domestic Convertible Corporate Bonds (Including
Secured or Unsecured Convertible Corporate Bonds).
c.Approval to release non-compete restrictions on newly elected
directors and authorized representatives.
7.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Chunghwa Chemical Synthesis & Biotech Co. Ltd. published this content on 25 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 May 2022 16:12:07 UTC.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. 
